Dapagliflozin treatment in patients with chronic kidney disease associated with autosomal dominant polycystic kidney disease.

ABSTRACT:

Introduction

The DAPA-CKD study showed a protective effect of dapagliflozin on kidney function in chronic kidney disease (CKD) patients with and without diabetes mellitus. Although dapagliflozin is expected to be effective also in CKD patients with autosomal dominant polycystic kidney disease (ADPKD), its efficacy and safety in this population remain unknown because ADPKD was an exclusion criterion in the DAPA-CKD study. Therefore, we evaluated the effects of dapagliflozin in CKD patients with ADPKD.

Methods

We performed a retrospective observational study of seven patients with ADPKD treated with dapagliflozin at Toranomon Hospital, Tokyo, Japan. We analyzed changes in estimated glomerular filtration rate (eGFR) slope and annual height-corrected total kidney volume before a

SUBMITTER: Yoshimoto M 

PROVIDER: S-EPMC11292219 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature